Pralatrexate As a Bridge to Allogeneic Hematopoietic Stem Cell Transplantation in a Patient with Advanced-stage Extranodal Nasal-type Natural Killer/T Cell Lymphoma Refractory to First-line Chemotherapy: a Case Report

Overview

Journal J Med Case Rep

Publisher Biomed Central

Specialty General Medicine

Date 2020 Mar 19

PMID 32183896

Authors

Yao-Chung Liu

Ting-An Lin

Hao-Yuan Wang

Po-Shen Ko

Chia-Jen Liu

Liang-Tsai Hsiao

Sheng-Hsuan Chien

Jyh-Pyng Gau

Affiliations

Soon will be listed here.

Abstract

Background: Extranodal natural killer/T cell lymphoma, nasal type, is one of the more common subtypes of mature T cell lymphoma, especially in the Far East Asian population. This aggressive histologic subtype of peripheral T cell lymphomas is frequently susceptible to exposure of Epstein-Barr virus infection. The optimal treatment is not well elucidated. For stage IV disseminated extranodal natural killer/T cell lymphoma, induction chemotherapy with consolidative autologus or allogeneic hematopoietic stem cell transplantation is recommended as the major first-line treatment. However, there is controversy over which type of chemotherapy is most appropriate and effective as a bridge to autologus or allogeneic hematopoietic stem cell transplantation in patients with newly diagnosed disseminated advanced-stage or relapsed extranodal natural killer/T cell lymphoma because of cancer chemoresistance or associated complications. Pralatrexate is the first US Food and Drug Administration-approved novel agent for the treatment of refractory/recurrent peripheral T cell lymphomas. In our case, pralatrexate was used as a successful bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage disseminated extranodal natural killer/T cell lymphoma refractory to first-line chemotherapy.

Case Presentation: We presented a case report of a 29-year-old Asian man diagnosed as having stage IV disseminated extranodal natural killer/T cell lymphoma, nasal type, with skin and bone marrow involvement, whose disease was primary refractory to first-line dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy, but obviously responded to treatment with two cycles of single-agent pralatrexate treatment. Monitoring Epstein-Barr virus viremia revealed dramatic downregulation. In addition to complete remission of the involvement of bone marrow and nasal cavity, skin involvement also obtained partial remission. The extranodal natural killer/T cell lymphoma successfully achieved complete remission after a bridge to allogeneic hematopoietic stem cell transplantation.

Conclusions: This is the first study to present pralatrexate as a successful bridge to allogeneic hematopoietic stem cell transplantation in a 29-year-old Asian male patient with advanced-stage extranodal natural killer/T cell lymphoma refractory to first-line dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy. This case provides a novel treatment opinion for extranodal natural killer/T cell lymphoma, especially for the Far East Asian population.

References

Chim C, Ma S, Au W, Choy C, Lie A, Liang R . Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood. 2003; 103(1):216-21. DOI: 10.1182/blood-2003-05-1401. View

Tse E, Kwong Y . The diagnosis and management of NK/T-cell lymphomas. J Hematol Oncol. 2017; 10(1):85. PMC: 5391564. DOI: 10.1186/s13045-017-0452-9. View

OConnor O, Pro B, Pinter-Brown L, Bartlett N, Popplewell L, Coiffier B . Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29(9):1182-9. PMC: 3083873. DOI: 10.1200/JCO.2010.29.9024. View

Kharfan-Dabaja M, Kumar A, Ayala E, Hamadani M, Reimer P, Gisselbrecht C . Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood.... Biol Blood Marrow Transplant. 2017; 23(11):1826-1838. DOI: 10.1016/j.bbmt.2017.07.027. View

Au W, Pang A, Choy C, Chim C, Kwong Y . Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood. 2004; 104(1):243-9. DOI: 10.1182/blood-2003-12-4197. View

Ahn H, Kim S, Hwang D, Ko Y, Tang T, Lim S . Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Invest New Drugs. 2012; 31(2):469-72. DOI: 10.1007/s10637-012-9889-4. View

Kanate A, DiGilio A, Ahn K, Al Malki M, Jacobsen E, Steinberg A . Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. Br J Haematol. 2017; 182(6):916-920. PMC: 5796874. DOI: 10.1111/bjh.14879. View

Cai Q, Cai J, Fang Y, Young K . Epstein-Barr Virus-Positive Natural Killer/T-Cell Lymphoma. Front Oncol. 2019; 9:386. PMC: 6527808. DOI: 10.3389/fonc.2019.00386. View

Yamaguchi M, Kwong Y, Kim W, Maeda Y, Hashimoto C, Suh C . Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol. 2011; 29(33):4410-6. DOI: 10.1200/JCO.2011.35.6287. View

10.

Lee J, Park Y, Kim W, Lee S, Ryoo B, Yang S . Extranodal nasal type NK/T-cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy. Eur J Cancer. 2005; 41(10):1402-8. DOI: 10.1016/j.ejca.2005.03.010. View

11.

Kwong Y, Kim W, Lim S, Kim S, Tang T, Tse E . SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group. Blood. 2012; 120(15):2973-80. DOI: 10.1182/blood-2012-05-431460. View

12.

Kim W, Jeong Nam S, Kim S, Kim T, Heo D, Kim C . Prognostic implications of CD30 expression in extranodal natural killer/T-cell lymphoma according to treatment modalities. Leuk Lymphoma. 2014; 56(6):1778-86. DOI: 10.3109/10428194.2014.974048. View

13.

Kwong Y, Pang A, Leung A, Chim C, Tse E . Quantification of circulating Epstein-Barr virus DNA in NK/T-cell lymphoma treated with the SMILE protocol: diagnostic and prognostic significance. Leukemia. 2013; 28(4):865-70. DOI: 10.1038/leu.2013.212. View

14.

Tse E, Chan T, Koh L, Chng W, Kim W, Tang T . Allogeneic haematopoietic SCT for natural killer/T-cell lymphoma: a multicentre analysis from the Asia Lymphoma Study Group. Bone Marrow Transplant. 2014; 49(7):902-6. DOI: 10.1038/bmt.2014.65. View

15.

Kim S, Yoon D, Jaccard A, Chng W, Lim S, Hong H . A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016; 17(3):389-400. DOI: 10.1016/S1470-2045(15)00533-1. View

16.

Hui J, Przespo E, Elefante A . Pralatrexate: a novel synthetic antifolate for relapsed or refractory peripheral T-cell lymphoma and other potential uses. J Oncol Pharm Pract. 2011; 18(2):275-83. DOI: 10.1177/1078155211420605. View

17.

Wang L, Wang H, Wang J, Xia Z, Lu Y, Huang H . Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015; 6(30):30317-26. PMC: 4745801. DOI: 10.18632/oncotarget.4505. View